Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value.
Humans
Urinary Bladder Neoplasms
/ blood
Fibronectins
/ blood
BCG Vaccine
/ therapeutic use
Male
Female
Administration, Intravesical
Middle Aged
Aged
Prognosis
Neoplasm Invasiveness
Adjuvants, Immunologic
/ therapeutic use
Polymorphism, Genetic
Prospective Studies
Neoplasm Recurrence, Local
/ blood
Biomarkers, Tumor
/ blood
Non-Muscle Invasive Bladder Neoplasms
BCG
Bladder cancer
Fibronectin
Gene Polymorphism
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
13
06
2024
accepted:
12
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy.
METHODS
METHODS
Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR.
RESULTS
RESULTS
The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker.
CONCLUSIONS
CONCLUSIONS
The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
Identifiants
pubmed: 39342212
doi: 10.1186/s12894-024-01592-8
pii: 10.1186/s12894-024-01592-8
doi:
Substances chimiques
Fibronectins
0
BCG Vaccine
0
Adjuvants, Immunologic
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Mersin University Scientific Research Projects Unit
ID : BAP 2022-1-TP3-4563.
Informations de copyright
© 2024. The Author(s).
Références
Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8.
Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–41.
doi: 10.1016/j.eururo.2012.07.033
pubmed: 22877502
Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E et al. Bladder Cancer and risk factors: data from a multi-institutional long-term analysis on Cardiovascular Disease and Cancer Incidence. J Pers Med. 2023;13.
Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F et al. Modified Glasgow Prognostic score as a predictor of recurrence in patients with high Grade Non-muscle invasive bladder Cancer undergoing intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel). 2022;12.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023;72:2961–70.
doi: 10.1007/s00262-023-03469-5
pubmed: 37248424
pmcid: 10991859
Rizzo A, Mollica V, Massari F. Expression of programmed cell death Ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line Immune checkpoint inhibitors Versus Chemotherapy: a systematic review and Meta-analysis. Eur Urol Focus. 2022;8:152–9.
doi: 10.1016/j.euf.2021.01.003
pubmed: 33516645
Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178:62–7.
doi: 10.1016/j.juro.2007.03.034
pubmed: 17499283
Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178:68–73.
doi: 10.1016/j.juro.2007.03.028
pubmed: 17499291
Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drǎgoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64:846–54.
doi: 10.1016/j.eururo.2013.03.059
pubmed: 23602406
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (TaT1 and Carcinoma in Situ) – 2019 update. Eur Urol. 2019;76:639–57.
doi: 10.1016/j.eururo.2019.08.016
pubmed: 31443960
Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. PharmacoEconomics. 2014;32:1093–104.
doi: 10.1007/s40273-014-0194-2
pubmed: 25056838
Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder Cancer across the European Union. Eur Urol. 2016;69:438–47.
doi: 10.1016/j.eururo.2015.10.024
pubmed: 26508308
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21:1315–30.
doi: 10.1007/BF03262330
pubmed: 14750899
NCCN Guidelines for Bladder Cancer. (Version 3.2023). National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417 . 2023. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417. Accessed 8 Oct 2023.
Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861–3.
doi: 10.1242/jcs.00059
pubmed: 12244123
Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005;24:389–99.
doi: 10.1016/j.matbio.2005.06.008
pubmed: 16061370
Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 1990;85:62–7.
doi: 10.1172/JCI114434
pubmed: 2404029
pmcid: 296387
Ratliffe TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol. 1988;139.
Mancini M, Righetto M, Zumerle S, Montopoli M, Zattoni F. The bladder EpiCheck Test as a non-invasive Tool based on the identification of DNA methylation in bladder Cancer cells in the urine: a review of published evidence. Int J Mol Sci. 2020;21:1–9.
doi: 10.3390/ijms21186542
Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130:6278–89.
doi: 10.1172/JCI139597
pubmed: 32817589
pmcid: 7685755
Sieverink CA, Batista RPM, Prazeres HJM, Vinagre J, Sampaio C, Leão RR et al. Clinical Validation of a Urine Test (Uromonitor-V2
Piatti P, Chew YC, Suwoto M, Yamada T, Jara B, Jia XY et al. Clinical evaluation of bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. Clin Epigenetics. 2021;13.
Deng L, Chao H, Deng H, Yu Z, Zhao R, Huang L et al. A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer. BMC Cancer. 2022;22.
Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder Cancer in a large prospective Multicenter Study. J Urol. 2017;197:1410–8.
doi: 10.1016/j.juro.2016.12.096
pubmed: 28049011
Eissa S, Swellam M, Sadek M, Mourad MS, Ahmady O, El, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002;168:465–9.
doi: 10.1016/S0022-5347(05)64659-9
pubmed: 12131289
Mutlu N, Turkeri L, Emerk K. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. Clin Chem Lab Med. 2003;41:1069–74.
doi: 10.1515/CCLM.2003.165
pubmed: 12964816
Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 2005;95:655–9.
doi: 10.1111/j.1464-410X.2005.05357.x
pubmed: 15705098
Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 2005;65:284–9.
doi: 10.1016/j.urology.2004.09.028
pubmed: 15708039
Hegele A, Kosche B, Schrader AJ, Sevinc S, Olbert PJ, Hofmann R, et al. [Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker]. Urologe A. 2008;47:1137–40.
doi: 10.1007/s00120-008-1825-z
pubmed: 18651122
Eissa S, Swellam M, Amin A, Balbaa ME, Yacout GA, El-Zayat TM. The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med Oncol. 2011;28:513–8.
doi: 10.1007/s12032-010-9422-6
pubmed: 21437743
Yang X, Huang H, Zeng Z, Zhao L, Hu P, He D, et al. Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis. Clin Biochem. 2013;46:1377–82.
doi: 10.1016/j.clinbiochem.2013.05.064
pubmed: 23735602
Guszcz T, Sankiewicz A, Gorodkiewicz E. Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients. J Pharm Biomed Anal. 2023;222.